Seattle Genetics (NASDAQ:SGEN) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Monday. The firm currently has a $42.10 target price on the stock. Zacks‘s price objective suggests a potential upside of 18.76% from the company’s current price. Seattle Genetics, Inc. (NASDAQ:SGEN) net profit margin is -22.30% and weekly performance is -8.41%. On last trading day company shares ended up $35.74. Analysts mean target price for the company is $45.15. Seattle Genetics, Inc. (NASDAQ:SGEN) distance from 50-day simple moving average is -3.39%.
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) shares fell -1.25% in last trading session and ended the day on $30.91. ISIS Gross Margin is -50.80% and its return on assets is -11.00%. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) quarterly performance is -15.71%.
On June 27,2014 EDAP TMS SA (Nasdaq: EDAP) announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP’s manufacturing site with no findings nor issuance of Form 483 observations. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) shares moved down -6.70% in last trading session and was closed at $5.43, while trading in range of $5.27-$5.95. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) year to date performance is 84.07%.
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and six months ended May 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) ended the last trading day at $2.95. Company weekly volatility is calculated as 12.92% and price to cash ratio as 12.11. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) showed a negative weekly performance of -20.97%.
On June 16,2014 Ventrus BioSciences, Inc. (NASDAQ: VTUS) is a development-stage specialty pharmaceutical company currently focused on the development of gastrointestinal products, including infections of the gastrointestinal system. Out of the four product candidates the company has in-licensed, VTUS is actively developing only two of them right now. These candidates include VEN 307, a diltiazem cream for the relief of pain associated with anal fissures, and VEN 310 for use as a colonic delivery mechanism, which is a pH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules and other treatments to the gastrointestinal tract. In addition, VTUS intends to in-license or acquire other development stage and pre-clinical compounds and biologics. Ventrus Biosciences Inc (NASDAQ:VTUS) weekly performance is 12.69%. On last trading day company shares ended up $1.51. Analysts mean target price for the company is $1.25. Ventrus Biosciences Inc (NASDAQ:VTUS) distance from 50-day simple moving average is 25.27%.